Kim Hyun S, Tsai Jason, Jacobs Michael A, Kamel Ihab R
The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):41-8. doi: 10.1016/j.jvir.2006.10.010.
To evaluate the feasibility and safety of percutaneous image-guided radiofrequency ablation (RFA) performed with moderate sedation for large symptomatic uterine leiomyomata.
Women with large (>5 cm in diameter) symptomatic subserosal and/or intramural uterine leiomyoma were recruited for a prospective study. Patients underwent percutaneous RFA following UAE. RFA using 5 cm treatment diameter expandable needle electrodes connected to a 460 kHz monopolar RF generator, which was performed with a target temperature and power set at 85 degrees C and 150 watts respectively, with a target temperature ablation time of 10 minutes. Patients were assessed for complications in perioperative and post-procedure periods at 24 hours and 1 month, and for symptom improvements at 6 months.
Thirty-five patients (mean 43.8 years +/- 6.2) were recruited. RFA targeting ablation size and temperature was achieved in 97% of the patients (34/35). There were no immediate percutaneous RFA-related complications. There was a self-limiting delayed drainage via the transabdominal RFA access track in one patient (2.9%), a urinary tract infection in one patient (2.9%) and post-embolization/post-ablation symptoms in three patients (8.6%). The mean transformed symptom severity score (SSS) as a part of the uterine fibroid symptom and quality of life (UFS-QOL) assessment shows that the improvements at 1 month were 24.3 points ( P < 0.001) and at 6 months were 40.4 points ( P < 0.001). Mean volume reduction of leiomyomata was 286.8 cm(3) or 56.5% ( P = 0.0015).
Percutaneous image-guided RFA as adjunctive to UAE under moderate sedation is feasible, and appears safe without significant morbidity in the treatment of large uterine leiomyomata.
评估在中度镇静下经皮影像引导射频消融术(RFA)治疗有症状的大型子宫平滑肌瘤的可行性和安全性。
招募有症状的大型(直径>5 cm)浆膜下和/或肌壁间子宫平滑肌瘤女性进行前瞻性研究。患者在子宫动脉栓塞术(UAE)后接受经皮RFA。使用连接到460 kHz单极射频发生器的5 cm治疗直径可扩张针状电极进行RFA,分别将目标温度和功率设置为85℃和150瓦,目标温度消融时间为10分钟。在围手术期和术后24小时及1个月评估患者并发症,在6个月时评估症状改善情况。
招募了35例患者(平均43.8岁±6.2)。97%的患者(34/35)实现了RFA靶向消融大小和温度。没有与经皮RFA直接相关的并发症。1例患者(2.9%)通过经腹RFA穿刺通道出现自限性延迟引流,1例患者(2.9%)发生尿路感染,3例患者(8.6%)出现栓塞后/消融后症状。作为子宫肌瘤症状和生活质量(UFS-QOL)评估一部分的平均转化症状严重程度评分(SSS)显示,1个月时改善了24.3分(P<0.001),6个月时改善了40.4分(P<0.001)。平滑肌瘤平均体积缩小286.8 cm³或56.5%(P = 0.0015)。
在中度镇静下,经皮影像引导RFA作为UAE的辅助治疗方法是可行的,且在治疗大型子宫平滑肌瘤时似乎安全,无明显发病率。